ClinicalTrials.gg
Not yet recruitingNCT07634263Updated Oct 23, 2026

Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

An observational study in Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression and Multiple Myeloma Refractory, sponsored by Odense University Hospital. Not yet recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Odense University Hospital · Observational

How we know

Updated Oct 23, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Multiple Myeloma with a site in Denmark — 22 open to participants now, 44 under way, 26 of them phase 3. Multiple Myeloma · Denmark.

Planned enrollment
9th of 14
50 · median 102
Started
2026
with 7 others
Observational
14 of 124
3 open now
Primary completion
2027-06
later than 19 of 43 live
Registered
118th of 124
by date
Lead sponsor
4 of 124
Odense University Hospital

Among the 124 studies in Multiple Myeloma with a site in Denmark, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is one of 8 that started in 2026, is one of 14 observational ones, reaches primary completion later than 19 of the 43 other live ones, and was the 118th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

22 of the 124 studies in Multiple Myeloma with a site in Denmark are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Multiple Myeloma with a site in Denmark, or all of them as a file.
02

Study summary

Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing.

Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood.

This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment.

The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.

Read the detailed description

Background Advances in treatment have improved survival for patients with hematologic malignancies, yet these patients remain at risk of severe complications and a high symptom burden.

As more patients require treatment and long-term care, the demand for hematologic services continues to grow. Home-based treatment is therefore expected to play an increasingly important role, with the potential to enhance patient-centered care, support daily life, improve quality of life, and reduce hospital burden. However, a proportion of patients do not meet the eligibility requirements for home-based treatment, and others choose to decline this option despite being offered the opportunity. Understanding the characteristics, experiences, and perspectives of these patients is essential for developing equitable, patient-centered approaches to treatment delivery and ensuring that home-based care models do not inadvertently exacerbate health disparities. Understanding this knowledge gap is crucial. These patients often undergo long, intensive treatment, and socially vulnerable patients may face additional practical, emotional, or social challenges. Home-based treatment could provide flexibility and support to reduce such inequalities. Without insight into why some patients decline or are ineligible for home-based treatment, there is a risk that these models will primarily serve more resourceful patients, potentially reinforcing health disparities.

The overall aim of this mixed methods study is to investigate reasons for declining or being deemed ineligible for home-based treatment among patients with hematologic malignancies, their caregivers and healthcare professionals.

This will be addressed with the following questions:

  1. Are there differences in medical, sociodemographic, and patient-reported outcomes between patients who decline or are ineligible for home-based treatment and those who accept it?
  2. What barriers exist to receive home-based treatment for a hematologic malignant disease?
  3. How do combined insights from the qualitative and quantitative data enhance understanding on barriers to home-based treatment? Methods Context This study is part of the Treat@Home research program, which aims to generate evidence on home-based interventions for patients with hematologic malignancies in Denmark. The program is anchored at the Department of Hematology, Zealand University Hospital (ZUH) and is led by the head of program and main applicant. It is supported by a management team and a national research group with interdisciplinary representatives from hematology departments across all Danish regions. In addition to several individual studies, the program includes two PhD projects investigating the implementation of home-based treatment with Daratumumab for multiple myeloma and Cytarabine for acute leukemia.

Design A mixed methods design will be applied, using quantitative and qualitative data. The qualitative study will apply interpretive description as a methodological framework. The qualitative and quantitative data will be merged, and through the mixed methods design, our aim is to converge two data sets and draw meta-inferences to gain deeper insights into the complexity of barriers to home-based treatment.

Participants In the quantitative sub-study, all patients from the Department of Hematology at Odense University Hospital (OUH) and ZUH who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. Inclusion will occur prospectively following enrollment. The aim is to include 50 participants, with 25 recruited from each site. While a formal sample size calculation is not appropriate at this stage, this number is justified on practical and methodological grounds.

In the qualitative sub-study, patients are eligible if they are invited to the quantitative sub-study but either declined or are deemed ineligible for home-based treatment. The aim is to include 20-25 participants, a range expected to achieve thematic saturation while allowing in-depth exploration of individual narratives. The final sample size will be determined based on Malterud's concept of information power, considering interview quality and participant variation.

Data collection In the quantitative sub-study, general medical data, comorbidities (Charlson Comorbidity Index), cancer-specific data, sociodemographic data, and patient reported outcomes will be collected at time of recruitment. Patient reported outcomes include health literacy (Health Literacy Questionnaire), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30), and caregiver burden (Caregiver Roles and Responsibilities Scale). In the qualitative sub-study, separate semi-structured interview guides for patients, caregivers and health professionals will be developed based on the literature to define key research topics. Participants can choose to be interviewed at home, the research facility, or during a hospital visit.

Analysis In the quantitative sub-study, data will be analyzed using descriptive statistics. Numerical variables will be reported as means and medians (with ranges) and compared using Student's t-test. Categorical variables will be presented as counts and percentages. Differences between patients who accept or decline/are deemed ineligible will be assessed using appropriate tests, such as the Wilcoxon rank-sum test and Fisher's exact test. A p-value \<0.05 will be considered statistically significant.

In the qualitative sub-study, all interviews will be transcribed verbatim and analyzed using Braun and Clarke's thematic analysis framework. The six-step process includes: 1) familiarization with the data through repeated reading and listening, 2) generating meaningful units, 3) identifying initial themes, 4) reviewing themes, 5) defining and naming themes, and 6) reporting the findings. Steps 1-3 will be conducted by a trained research nurse and steps 4-5. Analyses will be performed using NVivo version 14. Ethical considerations The study will be registered with the Danish Protection Agency and Clinical Trials. Participants will receive written and verbal information, including assurances of confidentiality in line with the Helsinki Declaration, and written consent will be obtained at recruitment. Given participants' potential vulnerability, extra care will be taken to ensure voluntary participation, and they will have time to debrief and discuss their experiences.

Project feasibility This study is highly feasible due to its integration within the national Treat@Home research program, which provides established infrastructure, clinical networks, and experience. OUH and ZUH have both conducted home-based treatment studies with Daratumumab and Cytarabine, ensuring access to the target patient population and familiarity with study protocols. The research team includes experienced clinicians and researchers in hematology, patient-reported outcomes, and mixed-methods research. Recruitment is facilitated through ongoing Treat@Home studies, and the qualitative sample size is achievable using thematic saturation and information power principles. Data collection and analysis procedures are well-established, using validated instruments and software to ensure robust integration of quantitative and qualitative findings.

Limitations The mixed-methods design strengthens this study by combining quantitative and qualitative data to understand why some patients decline or are deemed ineligible for home-based treatment. Limitations include potential constraints from sample size, missing data, and recruitment challenges, particularly among socially vulnerable groups, which may introduce selection bias. The qualitative findings, while rich, may have limited transferability and depend on participants' willingness to share experiences. Despite these challenges, integrating both data types allows triangulation and nuanced insights, providing critical knowledge to guide future studies and develop interventions that promote equitable access to home-based hematology treatment.

03

Conditions studied

  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Multiple Myeloma Progression
  • Multiple Myeloma Refractory

Keywords

  • Hematologic Neoplasms
  • multiple myeloma
  • Home Care Services
  • Patient Acceptance of Health Care
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients from the Department of Hematology at Odense University Hospital and Zealand University Hospital who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. We aim to include 50 participants, with 25 recruited from each site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >=18 years old
  • diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.

Exclusion criteria

Exclusion Criteria:

- Dementia, psychotic disorders, or other cognitive impairments limiting participation.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients enrolled in a Treat@Home study

    Patients who are enrolled in one of the two Treat@Home studies will be invited to participate

  • Patients declining enrollment in a Treat@Home study

    Patients who are invited in one of the two Treat@Home studies but decline this invitation will be invited to participate

  • Patients deemed not eligible for enrollment in a Treat@Home study

    Patients deemed not eligible for enrollment in one of the two Treat@Home studies will be invited for enrollment

06

What researchers measure

Primary outcomes

  1. Perceptions - patient

    Semi-structured interviews with patients at inclusion

    Time frame: Day 1

  2. Perception - caregivers

    Semi-structured interviews with caregiver (together with patient) at inclusion

    Time frame: Day 1

  3. Perception - Healthcare staff

    Focus group interview with Healthcare staff at end of study (after inclusion of all patients) in regards to barriers and possibilities in home administration

    Time frame: At study completion (end of inclusion of all patients)

Secondary outcomes

  1. Biological sex

    male, female

    Time frame: Day 1

  2. Patient reported outcomes

    Health literacy was assessed using the Health Literacy Questionnaire (HLQ), which contains multiple domains scored on separate scales, with higher scores indicating better health literacy.

    Time frame: Day 1

  3. Patient Reported Outcome

    Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30; scores range from 0-100, with higher functional and global health scores indicating better quality of life and higher symptom scores indicating greater symptom burden).

    Time frame: Day 1

  4. Caregiver burden

    Caregiver burden was assessed using the Caregiver Roles and Responsibilities Scale (CRRS), with higher scores indicating greater caregiver burden.

    Time frame: Day 1

  5. Age

    Number

    Time frame: Day 1

  6. Residents

    Capital, Zealand, Southern, Middle, North

    Time frame: Day 1

  7. Distance to hospital from home address

    kilometer (number)

    Time frame: day 1

  8. Urbanicity

    1\. Cities (densely populated area), 2. Towns, 3. suburbs (intermediate density area), and 4. rural (thinly populated area)

    Time frame: Day 1

  9. Performance status

    0, 1, 2, 3, 4

    Time frame: Day 1

  10. Hematologic diagnosis

    multiple myeloma or acute myeloid leukemia

    Time frame: Day 1

  11. Diagnose subtype

    IgA, IgG, IgM, Light chain, non-secretory, plasma cell, de novo, secondary, or relapsed/refractory

    Time frame: Day 1

  12. Blasts in bone marrow

    Number

    Time frame: Day 1

  13. Planned treatment regime

    Mono-therapy or combination

    Time frame: Day 1

  14. Previous lines of treatment

    number

    Time frame: Day 1

  15. Time of diagnosis

    Date

    Time frame: day 1

  16. Weight

    kilogram (number)

    Time frame: Day 1

  17. Etnicity

    White, Inuit, other (text)

    Time frame: Day 1

  18. Civil status

    Married/cohabiting, widowed, divorced, single, other (text)

    Time frame: Day 1

  19. Number of children

    Number

    Time frame: Day 1

  20. Living situation

    Living with other, living alone, other

    Time frame: Day 1

  21. Educational level

    Folkeskole, Gymnasie, Kort videregående uddannelse (\<3 years), Middel videregående uddannelse (3-4 years), Lang videregående uddannelse (\>4 years), Erhvervsuddannelse, or other (text)

    Time frame: Day 1

  22. Employment status

    full-time, part-time, unemployed, retired, sick leave

    Time frame: Day 1

  23. Previous self-administered home-based treatment (e.g., injections or a medication pump)

    yes, no

    Time frame: Day 1

  24. Smoking habits

    Never, Former, Current

    Time frame: Day 1

  25. Alcohol use behaviour

    Never, Former, Current

    Time frame: Day 1

  26. Regularly follow up for other illnesses than MM/AML at the hospital or with your general practitioner (at least once a month)

    yes, no

    Time frame: Day 1

  27. Receive help from home care and/or visiting nurses on a daily basis

    yes, no

    Time frame: Day 1

  28. Nearest relative most involved in disease

    spouse, child, family member, friend, neighbor, other

    Time frame: Day 1

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Considering sharing data upon request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 7 months is below that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Jun 8, 2026
StartEst.
Nov 1, 2026was Jul 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Nov 1, 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Jul 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07634263
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Jannie Kirkegaard, RN
Contact
jannie.kirkegaard@rsyd.dk
+45 29648494
Kristina Nørskov, RN, PhD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion